AMGN Technical Analysis
As of date:7/13/2020
AMGN stock price:250.04
AMGN 50 DMA:233.20
AMGN 200 DMA:220.86
AMGN MACD (200-50):-12.34
AMGN RSI:66.52
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)66.52
Extremely
Oversold

Also see:
AMGN Market Cap History
AMGN Shares Outstanding History
AMGN YTD Return

Quotes delayed 20 minutes
Get Free SEC filing alerts for AMGN:
AMGN SEC Filing Email Alerts ServiceExternal link

Notable Two Hundred Day Moving Average Cross - DCPH
54 minutes ago


ADUS Crosses Below Key Moving Average Level
1 hour, 9 minutes ago


VRSN Crosses Below Key Moving Average Level
1 hour, 17 minutes ago


PSTG Makes Notable Cross Below Critical Moving Average
1 hour, 26 minutes ago


PKG Makes Bullish Cross Above Critical Moving Average
1 hour, 42 minutes ago


VGM Makes Notable Cross Below Critical Moving Average
1 hour, 42 minutes ago


AMETEK (AME) Shares Cross Above 200 DMA
1 hour, 50 minutes ago


CRTX Makes Notable Cross Below Critical Moving Average
19 hours, 25 minutes ago


ATNX Crosses Below Key Moving Average Level
19 hours, 25 minutes ago


HOOK Crosses Below Key Moving Average Level
19 hours, 25 minutes ago


Notable Two Hundred Day Moving Average Cross - APPN
19 hours, 25 minutes ago


Prevail Therapeutics (PRVL) Shares Cross Below 200 DMA
19 hours, 25 minutes ago


Restaurant Brands Breaks Below 200-Day Moving Average - Notable for RTBRF
19 hours, 59 minutes ago


CNXN Crosses Below Key Moving Average Level
20 hours, 10 minutes ago


Anaplan (PLAN) Shares Cross Below 200 DMA
20 hours, 10 minutes ago


More Technical Analysis News

AMGN Technical AnalysisAMGN RSI
Amgen is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. Co.'s products include: Enbrel® (etanercept), which is used in indications for the treatment of adult patients with moderately to severely active rheumatoid arthritis, patients with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and patients with active psoriatic arthritis; and Prolia® (denosumab), which is used for the treatment of postmenopausal women with osteoporosis at high risk of fracture or multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

When researching a stock like Amgen, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from AMGN Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for AMGN stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
AMGN DMAAMGN MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Amgen (AMGN) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

BAX Technical Analysis
BDX Technical Analysis
BIIB Technical Analysis
BMY Technical Analysis
BSX Technical Analysis
CAH Technical Analysis
CELG Technical Analysis
CNC Technical Analysis
COO Technical Analysis
DGX Technical Analysis
More Healthcare companies »

 

AMGN Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2020, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.